HomeNewsInterviewMarket volatility to be more intense than normal for 1-2 years: Kalpen Parekh of DSP Investment Managers

Market volatility to be more intense than normal for 1-2 years: Kalpen Parekh of DSP Investment Managers

Last year, what helped corporate profitability was significant reduction in expenses. Travel-costs, office costs, rental costs came down significantly. So, profitability improved because margins improved. "If this trend continues, we should see more stability in stock prices," says the President at DSP Investment Managers.

May 24, 2021 / 16:18 IST
Story continues below Advertisement
Kalpen Parekh, President, DSP Investment Managers
Kalpen Parekh, President, DSP Investment Managers

The very nature of the market is to fluctuate, whether there is COVID or not. Generally, once every three years, the market falls and then there is an upward journey. So, the inherent nature of market volatility will remain but intensity of volatility could be higher than what we witness in normal times, says Kalpen Parekh, President, DSP Investment Managers in an interaction with Moneycontrol's Swati Verma.

Kalpen has around 23 years of experience in sales across client segments, distribution and marketing. He was previously Managing Director and Head of Sales & Marketing at IDFC Mutual Fund. He has also served in Birla Sun Life Asset Management Company Limited and ICICI Prudential Asset Management Company Limited after beginning his career with L&T Finance Ltd.

Story continues below Advertisement

Edited excerpts:

The second wave of COVID-19 in India has been devastating. We are witnessing restrictions, lockdowns all over again. Given this scenario, what's your view on the current market?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show